Cambridge Investment Research Advisors, Inc. Halozyme Therapeutics, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $27.1 Billion
- Q2 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 7,014 shares of HALO stock, worth $415,088. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,014
Previous 7,368
4.8%
Holding current value
$415,088
Previous $300,000
22.33%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding HALO
# of Institutions
487Shares Held
123MCall Options Held
208KPut Options Held
66.3K-
Black Rock Inc. New York, NY17.6MShares$1.04 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$762 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$344 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$239 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$220 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.24B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...